IWBI Crosses Major Global Milestones in Advancing Health and Well-Being
1.2.2021 17:00:00 EET | Business Wire | Press release
The International WELL Building Institute (IWBI), the global authority on how we can use our buildings and communities to advance the health and well-being of the people inside, announced today that WELL projects have now crossed the 1.5 billion square foot mark across more than 80 countries. The milestone is evidence of accelerating global adoption and tremendous growth from less than a year ago, when WELL projects surpassed 500 million square feet in nearly 60 countries.
In June 2020, IWBI launched the WELL Health-Safety Rating, leveraging its existing expertise and feedback from the 600-member IWBI Taskforce on COVID-19. Drawing on a subset of features from the WELL Building Standard (WELL), the WELL Health-Safety Rating is an evidence-based, third-party verified rating for all new and existing buildings and space types that is focused on operational policies, maintenance protocols, emergency plans and stakeholder engagement strategies to help organizations prioritize the health and safety of their staff, visitors and stakeholders, and get back to business during these pandemic times.
More than 8,500 facilities have enrolled in the WELL Health-Safety Rating to date, including iconic buildings like Yankee Stadium and the Empire State Building, global financial service organizations like JPMorgan Chase, hotel leaders like Aimbridge Hospitality, telecommunications organizations like T-Mobile, real estate developers like Brookfield Properties and Kilroy Realty, fitness organizations like Life Time, and many others.
“The pandemic quickly shifted the conversation on health, and IWBI’s role in helping mitigate the impact of the virus and supporting people’s safety and well-being is now more clear than ever,” said Paul Scialla, Founder of IWBI and CEO of its parent company, Delos.
“The pace of adoption has been remarkable, with registrations across WELL offerings now averaging 2 million square feet every day,” said Rachel Hodgdon, IWBI President and CEO. “This is thanks to our dedicated community from around the world - our WELL APs, WELL Faculty, members, customers and advisors.”
WELL APs and WELL Faculty are an active and growing community that brings education about WELL to colleagues and clients around the world. Over 16,000 individuals have registered for or achieved the WELL AP credential and have helped IWBI quickly respond to rising demand.
“These are enormous accomplishments in the six years since WELL first launched,” continued Hodgdon. “While the pandemic has disrupted so much of our lives, it’s also presented us with the opportunity to grow a movement that has the potential to do so much good. Each of these milestones is an affirmation of the need for people first places, and we can’t wait to share what we have in store.”
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is a public benefit corporation and the world’s leading organization focused on deploying people first places to advance a global culture of health. IWBI mobilizes its community through the administration of the WELL Building Standard (WELL) and the WELL Health-Safety Rating, management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellbeing everywhere. More information on WELL can be found here.
International WELL Building Institute pbc is a wholly owned subsidiary of Delos. International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL Portfolio, WELL Portfolio Score, The WELL Conference, We Are WELL, the WELL Community Standard, WELL Health-Safety Rating, WELL Health-Safety Rated, WELL Health-Equity, WELL and others, and their related logos are trademarks or certification marks of International WELL Building Institute in the United States and other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005203/en/
Contact information
Jamie Matos
media@wellcertified.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Linnea Achieves CEP Certification for Cannabidiol Isolate3.3.2026 09:25:00 EET | Press release
Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP). The CEP serves to attest that the quality of an active pharmaceutical ingredient (API) is adequately controlled by the monographs of the European Pharmacopoeia, ensuring its safety, quality and conformity for use in medicinal products in Europe. Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), the CEP represents an independent validation of consistency, safety, and regulatory compliance for the European market. This consequently simplifies the marketing authorization (MA) process for new medicines, as a detailed evaluation of the active substance by regulatory authorities is not required. This milestone represents a significant achievement for the company and reinforces its commitment to delivering consistent and high-quality cannabinoid ingredients. The certification provides customers and partners with as
Quectel Expands Small Cell Antennas Portfolio With Five New Products3.3.2026 09:00:00 EET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, has introduced five new small cell antennas to add further functionality and provide greater flexibility and choice for customers designing and implementing small cell deployments. The new antennas bring an additional range of form factors, mounting options and performance characteristics to the Quectel antenna range. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302915004/en/ Quectel expands small cell antennas portfolio with five new products “Whether you’re looking for an antenna to support critical wireless communications, dense stadium usage scenarios or ultimate capacity, these five new Quectel antennas have been designed to meet your needs,” says David Wei, Antenna Product Head, Quectel Wireless Solutions. “The new antennas augment our already comprehensive range of antennas, bring further choice and add capabilities for developers and enginee
Quectel Introduces FGH200M Wi-Fi HaLow Module for massive IoT Deployments3.3.2026 09:00:00 EET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FGH200M long range, low power Wi-Fi HaLow module. Based on the Morse Micro MM8108 chipset and operating in the sub-1GHz license exempt frequency band, the module delivers enhanced penetration and broader coverage, over a range of approximately 1km, while supporting low power consumption and large-scale device connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302200601/en/ Quectel introduces FGH200M Wi-Fi HaLow module for massive IoT deployments The FGH200M module adopts the IEEE 802.11ah wireless networking protocol, also known as Wi-Fi HaLow, operating in the license-exempt Sub-1GHz spectrum. Designed to meet the evolving requirements of IoT connectivity, the FGH200M delivers extended Sub-1GHz signal coverage, enabling reliable device control at distances of up to one kilometer. “We’re excited to unveil th
Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis3.3.2026 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of multiple sterile pustules on the palms and soles. Patients often experience pain and pruritus of the skin, and the condition can be accompanied by nail involvement and joint pain. Because lesions on the palms are visible to others and lesions on the soles can cause pain while walking, daily functioning can be significantly restricted, leading in a substantial reduction in quality of life. PPP has a pathophysiology distinct from psoriasis and pustular psoriasis, and treatment can be challenging, unde
IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses2.3.2026 23:15:00 EET | Press release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
